Pharmacokinetic Studies with a Dual-Release Formulation of Levodopa, a Novel Principle in the Treatment of Parkinson’s Disease

Publisher： Karger

E-ISSN： 1421-9913|39|2|119-124

ISSN： 0014-3022

Source： European Neurology, Vol.39, Iss.2, 1998-02, pp. : 119-124

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

COMT Inhibition by Tolcapone Further Improves Levodopa Pharmacokinetics when Combined with a Dual-Release Formulation of Levodopa/Benserazide

By  

European Neurology, Vol. 41, Iss. 4, 1999-05 ,pp. : 206-211

Karger

Access to resources Recommend Favorite

Treatment of Early Parkinson’s Disease

By  

European Neurology, Vol. 61, Iss. 4, 2009-01 ,pp. : 193-205

Karger

Access to resources Recommend Favorite

Treatment of Early Parkinson’s Disease

By  

European Neurology, Vol. 61, Iss. 4, 2009-01 ,pp. : 206-215

Karger

Access to resources Recommend Favorite

Comparative Single- and Multiple-Dose Pharmacokinetics of Levodopa and 3-O-Methyldopa following a New Dual-Release and a Conventional Slow-Release Formulation of Levodopa and Benserazide in Healthy Volunteers

By  

European Neurology, Vol. 49, Iss. 1, 2002-12 ,pp. : 39-44

Karger

Access to resources Recommend Favorite

When Do Levodopa Motor Fluctuations First Appear in Parkinson’s Disease?

By  

European Neurology, Vol. 63, Iss. 5, 2010-03 ,pp. : 257-266

Karger

Access to resources Recommend Favorite